Rebecca S. Blue

Rebecca S. Blue

Auto-generated profile, based on publicly available information

Rebecca S. Blue

School of Public and Population Health, University of Texas Medical Branch, Galveston, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2019 in npj Microgravity
Verified
Journal Article
Open access
PDF file
RBRebecca S. Blue
Rebecca S. Blue
TBTina M. Bayuse
Tina M. Bayuse
VDVernie R. Daniels
Vernie R. Daniels
VWVirginia E. Wotring
Virginia E. Wotring
RSRahul Suresh
Rahul Suresh
EAErik L. Antonsen
Erik L. Antonsen
In order to maintain crew health and performance during long-duration spaceflight outside of low-Earth orbit, NASA and its international partners must be capable of providing a safe and effective pharmacy. Given few directed studies of pharmaceuticals in the space environment, it is difficult to characterize pharmaceutical effectiveness or stability during spaceflight; this in turn makes it challenging to select an appropriate formulary for exploration. Here, we present the current state of literature regarding pharmaceutical stability, metabolism, and effectiveness during spaceflight. In particular, we have attempted to highlight the gaps in current knowledge and the difficulties in translating terrestrial-based drug studies to a meaningful interpretation of drug stability, safety, and effectiveness in space. We hope to identify high-yield opportunities for future research that might better define and mitigate pharmaceutical risk for exploration missions.

6 June 2019 in npj Microgravity
Verified
Journal Article
Open access
PDF file
RBRebecca S. Blue
Rebecca S. Blue
JCJeffery C. Chancellor
Jeffery C. Chancellor
EAErik L. Antonsen
Erik L. Antonsen
TBTina M. Bayuse
Tina M. Bayuse
VDVernie R. Daniels
Vernie R. Daniels
VWVirginia E. Wotring
Virginia E. Wotring
As human spaceflight seeks to expand beyond low-Earth orbit, NASA and its international partners face numerous challenges related to ensuring the safety of their astronauts, including the need to provide a safe and effective pharmacy for long-duration spaceflight. Historical missions have relied upon frequent resupply of onboard pharmaceuticals; as a result, there has been little study into the effects of long-term exposure of pharmaceuticals to the space environment. Of particular concern are the long-term effects of space radiation on drug stability, especially as missions venture away from the protective proximity of the Earth. Here we highlight the risk of space radiation to pharmaceuticals during exploration spaceflight, identifying the limitations of current understanding. We further seek to identify ways in which these limitations could be addressed through dedicated research efforts aimed toward the rapid development of an effective pharmacy for future spaceflight endeavors.

1 October 2012 in Aviation, Space, and Environmental Medicine
Verified
Journal Article
Closed access
RBRebecca S. Blue
Rebecca S. Blue
JRJon M. Riccitello
Jon M. Riccitello
JTJulia Tizard
Julia Tizard
RHRichard J. Hamilton
Richard J. Hamilton
JVJames M. Vanderploeg
James M. Vanderploeg
Blue RS, Riccitello JM, Tizard J, Hamilton RJ, Vanderploeg JM. Commercial spaceflight participant G-force tolerance during centrifuge-simulated suborbital flight. Aviat Space Environ Med 2012; 83:929–34. Introduction: Medical knowledge of the human body in microgravity and hypergravity is based upon studies of healthy individuals well-conditioned for such environments. Little data exist regarding the effects of spaceflight on untrained commercial passengers. We examined the responses of potential spaceflight participants (SFP) to centrifuge G-force exposure. Methods: There were 77 individuals (65 men, 12 women), 22-88 yr old, who underwent 6 centrifuge runs over 48 h. Day 1 consisted of two +Gz runs (peak = 3.5+Gz, run 2) and two +Gx runs (peak = 6.0+Gx, run 4). Day 2 consisted of two runs approximating a suborbital spaceflight profile. Data included blood pressure, electrocardiogram, and postrun questionnaires regarding motion sickness, disorientation, greyout, and other symptoms. Results: Of the 77 participants, average age was 50.4 ± 12.7 yr. Average heart rate (HR) varied by sex and direction of G-exposure (+Gz: F 150 ± 19, M 123 ± 27; +Gx: F 135 ± 30, M 110 ± 27). Age and peak HR were inversely related (HR < 120bpm: 60.2 ± 12.2 yr, HR > 120: 47.1 ± 10.9 yr). HR during peak G-exposure for the final run was associated with post-run imbalance (no imbalance: HR 126 ± 26, imbalance: HR 145 ± 21); no other significant hemodynamic change, sex, or age variation was associated with imbalance. Age and greyout were inversely associated; there was no association between greyout and vital sign change, sex, or G-force magnitude. Baseline/pretrial mean arterial pressure (MAP) was not associated with any symptoms. Discussion: The results suggest that most individuals with well-controlled medical conditions can withstand acceleration forces involved in launch/landing profiles of commercial spaceflight vehicles. Further investigation will help refine which conditions present significant risk during suborbital flight and beyond.

1 February 2018 in Aerospace Medicine and Human Performance
Verified
Journal Article
Closed access
EAErik L. Antonsen
Erik L. Antonsen
RMRobert A. Mulcahy
Robert A. Mulcahy
DRDavid Rubin
David Rubin
RBRebecca S. Blue
Rebecca S. Blue
MCMichael A. Canga
Michael A. Canga
RSRonak Shah
Ronak Shah
INTRODUCTION: The provision of medical care in exploration-class spaceflight is limited by mass, volume, and power constraints, as well as limitations of available skillsets of crewmembers. A quantitative means of exploring the risks and benefits of inclusion or exclusion of onboard medical capabilities may help to inform the development of an appropriate medical system. A pilot project was designed to demonstrate the utility of an early tradespace analysis tool for identifying high-priority resources geared toward properly equipping an exploration mission medical system.METHODS: Physician subject matter experts identified resources, tools, and skillsets required, as well as associated criticality scores of the same, to meet terrestrial, U.S.-specific ideal medical solutions for conditions concerning for exploration-class spaceflight. A database of diagnostic and treatment actions and resources was created based on this input and weighed against the probabilities of mission-specific medical events to help identify common and critical elements needed in a future exploration medical capability.RESULTS: Analysis of repository data demonstrates the utility of a quantitative method of comparing various medical resources and skillsets for future missions. Directed database queries can provide detailed comparative estimates concerning likelihood of resource utilization within a given mission and the weighted utility of tangible and intangible resources.DISCUSSION: This prototype tool demonstrates one quantitative approach to the complex needs and limitations of an exploration medical system. While this early version identified areas for refinement in future version development, more robust analysis tools may help to inform the development of a comprehensive medical system for future exploration missions.Antonsen EL, Mulcahy RA, Rubin D, Blue RS, Canga MA, Shah R. Prototype development of a tradespace analysis tool for spaceflight medical resources. Aerosp Med Hum Perform. 2018; 89(2):108–114.

1 September 2021 in REACH
Verified
Journal Article
Closed access
JSJon G. Steller
Jon G. Steller
RBRebecca Blue
Rebecca Blue
CZChristopher Zahner
Christopher Zahner
EFEmily H. Frisch
Emily H. Frisch
TBTina Bayuse
Tina Bayuse
RJRichard T. Jennings
Richard T. Jennings

1 October 2013 in Aviation, Space, and Environmental Medicine
Verified
Journal Article
Closed access
RBRebecca S. Blue
Rebecca S. Blue
JHJoseph C. Hudson
Joseph C. Hudson
MRMichael F. Rieders
Michael F. Rieders
JJJohn T. James
John T. James
PSPhilip C. Stepaniak
Philip C. Stepaniak
Blue RS, Hudson JC, Rieders MF, James JT, Stepaniak PC. Medical management of a potentially toxic accidental trialkylamine ingestion during spaceflight. Aviat Space Environ Med 2013; 84:1100–4. Introduction: To reduce excessive iodine consumption by astronauts, the National Aeronautics and Space Administration (NASA) has developed various methods of removing residual iodine after iodine-based water purification aboard spacecraft. The Low Iodine Residual System (LIRS) was developed as an iodine removal system for use aboard the space shuttle. This is a case report of an accidental, potentially toxic ingestion by astronauts aboard a space shuttle mission following exposure to contaminated water from LIRS filtration and the medical response operations that followed. Case Report : Astronauts ingested significant levels of trialkylamines from water that had passed through gamma-irradiated, de-iodination resin in the LIRS hardware. Medical response operations included crew evaluations, consultations with toxicologists and systems experts, hardware testing, contaminant evaluation, and close crewmember follow-up. Discussion : Despite the significant ingestion there were no adverse clinical symptoms in any of the exposed astronauts; however, the case highlights a simple pitfall in the classification of hardware that ultimately lead to a potentially harmful toxic ingestion among the crewmembers, and the real-time response of medical personnel to ensure crew safety.